Skip to main content
. 2018 Dec 19;7(3):597–618. doi: 10.1016/j.jcmgh.2018.12.004

Figure 6.

Figure 6

GalNAc-Stk25 ASO treatment ameliorated liver steatosis in obese mice. Mice were treated with GalNAc-Stk25 ASO (12.5 mg/kg/wk), Stk25 ASO (50 mg/kg/wk), GalNAc-control ASO (12.5 mg/kg/wk), or placebo (PBS) for 6 weeks. (A) Representative images of whole liver; representative liver sections stained with H&E or Oil Red O for lipids. (B) Representative liver sections stained with H&E from age-matched chow diet–fed lean mice as well as Stk25 knockout mice and their wild-type littermates fed a high-fat diet. Stk25 knockout mice were a gift from B. Howell (State University of New York Upstate Medical University, Syracuse, NY). (C) Quantification of total lipid area in liver sections. (D) TAG content in liver extract. (C and D) Data are means ± SD from 6–8 mice per group. Scale bars: 100 μm. CD, chow diet; cntr, control; HFD, high-fat diet; KO, knockout; WT, wild-type. *P < .05, **P < .01.